Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus DRYTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus DRYTEC.
DRIXORAL vs DRYTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Category C
Category C
Antihistamine/Decongestant
Decongestant